Jeg har faktisk ikke tatt meg skikkelig tid til å dykke dypt ned i q2-rapporten til Ultimovacs. Før nå. Limer inn et par spennende utsagn under:
- The vaccine is simple to manufacture and requires no sophisticated infrastructure. If the ongoing clinical development and testing of Ultimovacs’ cancer vaccine demonstrates that the vaccine gives clinical benefit to cancer patients, the potential clinical use of UV1 and related revenues could be very high.
- The three Phase II clinical trials will enroll more than 400 patients. Two of the trials will be in close collaboration with two big pharma companies and two international networks of specialized cancer centers. The ongoing clinical trials represent a strong platform for Ultimovacs to move towards a possible registration of the universal cancer vaccine, UV1.
- Ultimovacs continuously has or pursues discussions to enter into collaborations with cancer institutions and pharmaceutical companies in order to document the effect and safety of UV1 in other cancer types and in combinations with different cancer treatments.
- Pending confirmation of the safety of the TET technology through the Phase I TENDU trial and further pre-clinical development, the ambition is to apply the TET technology and identify new universal cancer vaccine candidates to move into clinical development.
